Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 27;5(4):280-287.
doi: 10.1093/abt/tbac024. eCollection 2022 Oct.

The emergence of AntibodyPlus: the future trend of antibody-based therapeutics

Yong Zhu  1 , Shawn Shouye Wang  2   3 , Zhaohui Sunny Zhou  4   5 , Mitchell Ho  6   7
Affiliations
Review

The emergence of AntibodyPlus: the future trend of antibody-based therapeutics

Yong Zhu et al. Antib Ther. .

Abstract

To date, close to 100 canonical monoclonal antibody drugs have been approved by the FDA; furthermore, a number of antibody-derived therapeutics in nontraditional formats have reached late development stages and the market, and many more are being evaluated in early-stage development. To better reflect this trend and to set up a framework for forward thinking, we herein introduce the concept of AntibodyPlus, embracing any therapeutics with an antibody component. AntibodyPlus therapeutics contain effector modules, in the form of small molecules, nucleic acids, proteins or even cells, to enhance their therapeutic activities against cancer, virus infection and other diseases. In this short review, we discuss historic perspective and current status of therapeutic antibody development, and the scope and categories of AntibodyPlus therapeutics along with their advantages, applications and challenges. We also present several examples that highlight their design principles, potentials and future trends.

Keywords: Antibody therapeutics; antibody conjugates; antibodyPlus; hybrid modality; noncanonical antibody.

PubMed Disclaimer

Conflict of interest statement

Dr. Yong Zhu is a member of the Chinese Antibody Society (CAS). Dr. Shawn Shouye Wang is an employee and shareholders of WuXi Biologics. Shawn Shouye Wang was the founding president of CAS and has been serving as a member of the Board of Directors for CAS. Antibody Therapeutics is the official journal of Chinese Antibody Society. Prof. Mitchell Ho has also been serving as a member of the Board of Directors for CAS and is also the Editor-in-Chief of Antibody Therapeutics. Prof. Zhaohui Sunny Zhou is a co-founder and equity holder of NIRa Biosciences, and a member of editorial board of Antibody Therapeutics. All the authors are blinded from reviewing or making decisions on the manuscript.

Figures

Figure 1
Figure 1
Antibody or antibody-containing therapeutics approved by the FDA as of 31 March 2022.
Figure 2
Figure 2
The categories and subcategories of AntibodyPlus therapeutics. ADAR, adenosine deaminase acting on RNA; ADC, antibody drug conjugate; ASO, antisense oligonucleotide; bsAb, bispecific antibody; EV, extracellular vesicles; CAR, chimeric antigen receptor; GP, glycopeptide; LNP, lipid nanoparticle; LYTAC, lysosome-targeting chimera; MA, macrophage cells; msAb, multispecific antibody; miRNA, microRNA; NK, natural killer cells; PROTAC, proteolysis-targeting chimera; siRNA, small interfering RNA; saRNA, small activating RNA. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mullard, A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 2021; 20: 491–5. - PubMed
    1. The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US. https://www.antibodysociety.org/resources/approved-antibodies/ (31 March 2022, last accessed).
    1. O'Leary, MC, Lu, X, Huang, Y et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 2019; 25: 1142–6. - PubMed
    1. Goodridge, JP, Mahmood, S, Zhu, H et al. FT596: translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies. Blood 2019; 134: 301.
    1. Gabrusiewicz, K, Anderson, N, Lu, X et al. Abstract B65: CT-0508, a novel CAR macrophage product directed against HER2, promotes a proinflammatory tumor microenvironment. Cancer Immunol Res 2020; 8: B65–5.

LinkOut - more resources